摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,3S,4aR,8S,8aR)-methyl 8-hydroxy-2,3-dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate | 245054-31-3

中文名称
——
中文别名
——
英文名称
(2S,3S,4aR,8S,8aR)-methyl 8-hydroxy-2,3-dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate
英文别名
methyl (3S,4S,5R)-3-hydroxy-4,5-<(2S,3S)-2,3-dimethoxybutan-2,3-dioxy>-cyclohex-1-en-1-carboxylate;methyl (2S,3S,4aR,5S,8aR)-5-hydroxy-2,3-dimethoxy-2,3-dimethyl-4a,5,8,8a-tetrahydro-1,4-benzodioxine-7-carboxylate
(2S,3S,4aR,8S,8aR)-methyl 8-hydroxy-2,3-dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate化学式
CAS
245054-31-3
化学式
C14H22O7
mdl
——
分子量
302.324
InChiKey
QEKVKHCYCSPTAJ-AXMVNOCNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    140-142 °C(Solv: ethyl ether (60-29-7); pentane (109-66-0))
  • 沸点:
    407.8±45.0 °C(Predicted)
  • 密度:
    1.24±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.79
  • 拓扑面积:
    83.4
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

点击查看最新优质反应信息

文献信息

  • A pattern recognition approach to 14-epi-hydrophenanthrene core of the morphine alkaloids based on shikimic acid
    作者:Tung N. Dinh、Anqi Chen、Christina L.L. Chai
    DOI:10.1016/j.tet.2011.03.063
    日期:2011.5
    An expeditious and stereoselective construction of C-14-epimer of the tetracyclic hydrophenanthrene framework of the morphine alkaloids is described. The core structure is obtained in nine steps in 11% overall yield from shikimic acid via three key transformations: (i) coupling of shikimic acid with 2-iodoisovanillin at C-3 by double SN2 inversion to form the aryl ether 5; (ii) an intramolecular Heck
    描述了吗啡生物碱的四环氢菲骨架的C-14-受体的快速和立体选择性构建。通过三个关键的转化,从sh草酸通过九个步骤以11%的总收率获得核心结构:(i)double草酸与2-碘异香兰素在C-3处通过两次S N 2转化形成芳基醚5;(ii)分子内的Heck反应以构建二氢苯并呋喃环,和(iii)McMurry偶合以提供对菲核心。
  • Conversion of (−)-3-Dehydroshikimic Acid into Derivatives of the (+)-Enantiomer
    作者:Martin G. Banwell、Alison J. Edwards、Michael Essers、Katrina A. Jolliffe
    DOI:10.1021/jo034689c
    日期:2003.8.1
    (-)-3-DHS (1), a compound available in large quantity through "engineering" of the shikimic acid pathway, has been converted over eight steps into the methyl ester, ent-2, of the (+)-enantiomer. Methyl (+)-shikimate (15) and its C-3 epimer (ent-5) have also been prepared by related means.
    (-)-3-DHS(1)是通过the草酸途径的“工程化”而大量获得的化合物,经八步转化为(+)-对映体的甲酯ent-2。(+)-shi草酸甲酯(15)及其C-3差向异构体(ent-5)也已通过相关方法制备。
  • Efficient synthesis of (−)-methyl 3-epi-shikimate and methyl 3-epi-quinate by one-pot selective protection of trans-1,2-diols
    作者:Nuria Armesto、Miguel Ferrero、Susana Fernández、Vicente Gotor
    DOI:10.1016/s0040-4039(00)01507-0
    日期:2000.11
    have been achieved by in situ formation of the protecting group (2,2,3,3-tetramethoxybutane). The synthetic utility of the protected derivatives is demonstrated by the preparation of (−)-methyl 3-epi-shikimate and methyl 3-epi-quinate through a new and efficient route from the parent acids.
    通过原位形成保护基团(2,2,3,3-四甲氧基丁烷)可以实现sh草酸和奎尼酸的反式-1,2-二醇保护。受保护的衍生物的合成效用通过从母体酸通过新的有效途径制备(-)-3- Epi- shikimate甲酯和3- epi- quinate甲酯来证明。
  • New Approach to the Total Synthesis of (-)-Zeylenone from Shikimic Acid
    作者:Yi Zhang、An Liu、Zu Guang Ye、Jia Lin、Li Zhen Xu、Shi Lin Yang
    DOI:10.1248/cpb.54.1459
    日期:——
    The natural antitumor product (-)-zeylenone was prepared for the first time in a stereoselective synthesis from shikimic acid.
    从sh草酸立体选择性合成中首次制备了天然抗肿瘤产物(-)-玉米select酮。
  • Mycobacterium tuberculosis Shikimate Kinase Inhibitors: Design and Simulation Studies of the Catalytic Turnover
    作者:Beatriz Blanco、Verónica Prado、Emilio Lence、José M. Otero、Carmela Garcia-Doval、Mark J. van Raaij、Antonio L. Llamas-Saiz、Heather Lamb、Alastair R. Hawkins、Concepción González-Bello
    DOI:10.1021/ja405853p
    日期:2013.8.21
    Shikimate kinase (SK) is an essential enzyme in several pathogenic bacteria and does not have any counterpart in human cells, thus making it an attractive target for the development of new antibiotics. The key interactions of the substrate and product binding and the enzyme movements that are essential for catalytic turnover of the Mycobacterium tuberculosis shikimate kinase enzyme (Mt-SK) have been investigated by structural and computational studies. Based on these studies several substrate analogs were designed and assayed. The crystal structure of Mt-SK in complex with ADP and one of the most potent inhibitors has been solved at 2.15 angstrom. These studies reveal that the fixation of the diaxial conformation of the C4 and C5 hydroxyl groups recognized by the enzyme or the replacement of the C3 hydroxyl group in the natural substrate by an amino group is a promising strategy for inhibition because it causes a dramatic reduction of the flexibility of the LID and shikimic acid binding domains. Molecular dynamics simulation studies showed that the product is expelled from the active site by three arginines (Arg117, Arg136, and Arg58). This finding represents a previously unknown key role of these conserved residues. These studies highlight the key role of the shikimic acid binding domain in the catalysis and provide guidance for future inhibitor designs.
查看更多